Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.

Abstract : Dacarbazine (DTIC) is a cytotoxic drug widely used for melanoma treatment. However, the putative contribution of anticancer immune responses in the efficacy of DTIC has not been evaluated. By testing how DTIC affects host immune responses to cancer in a mouse model of melanoma, we unexpectedly found that both natural killer (NK) and CD8(+) T cells were indispensable for DTIC therapeutic effect. Although DTIC did not directly affect immune cells, it triggered the upregulation of NKG2D ligands on tumor cells, leading to NK cell activation and IFNγ secretion in mice and humans. NK cell-derived IFNγ subsequently favored upregulation of major histocompatibility complex class I molecules on tumor cells, rendering them sensitive to cytotoxic CD8(+) T cells. Accordingly, DTIC markedly enhanced cytotoxic T lymphocyte antigen 4 inhibition efficacy in vivo in an NK-dependent manner. These results underscore the immunogenic properties of DTIC and provide a rationale to combine DTIC with immunotherapeutic agents that relieve immunosuppression in vivo.
Document type :
Journal articles
Liste complète des métadonnées

https://www.hal.inserm.fr/inserm-00857892
Contributor : Grégoire Mignot <>
Submitted on : Wednesday, September 4, 2013 - 10:54:29 AM
Last modification on : Wednesday, September 12, 2018 - 1:27:45 AM

Links full text

Identifiers

Citation

Alice Hervieu, Cédric Rébé, Frédérique Végran, Fanny Chalmin, Mélanie Bruchard, et al.. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.. Journal of Investigative Dermatology, Nature Publishing Group, 2013, 133 (2), pp.499-508. ⟨10.1038/jid.2012.273⟩. ⟨inserm-00857892⟩

Share

Metrics

Record views

254